|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0003873,
umls-concept:C0008976,
umls-concept:C0030705,
umls-concept:C0031809,
umls-concept:C0034380,
umls-concept:C0184511,
umls-concept:C0205177,
umls-concept:C0335081,
umls-concept:C0393022,
umls-concept:C1261322,
umls-concept:C1274040,
umls-concept:C1512888,
umls-concept:C1516634
|
|
pubmed:issue |
1
|
|
pubmed:dateCreated |
2008-1-7
|
|
pubmed:abstractText |
To evaluate the effect of rituximab treatment on health-related quality of life (HRQOL) in patients with active rheumatoid arthritis (RA), who have had an inadequate response to disease-modifying antirheumatic drugs, including biologic agents.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Jan
|
|
pubmed:issn |
0315-162X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
35
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
20-30
|
|
pubmed:dateRevised |
2010-11-18
|
|
pubmed:meshHeading |
pubmed-meshheading:18050385-Antibodies, Monoclonal,
pubmed-meshheading:18050385-Antibodies, Monoclonal, Murine-Derived,
pubmed-meshheading:18050385-Arthritis, Rheumatoid,
pubmed-meshheading:18050385-Dose-Response Relationship, Drug,
pubmed-meshheading:18050385-Double-Blind Method,
pubmed-meshheading:18050385-Drug Therapy, Combination,
pubmed-meshheading:18050385-Female,
pubmed-meshheading:18050385-Humans,
pubmed-meshheading:18050385-Immunologic Factors,
pubmed-meshheading:18050385-Immunosuppressive Agents,
pubmed-meshheading:18050385-Male,
pubmed-meshheading:18050385-Methotrexate,
pubmed-meshheading:18050385-Middle Aged,
pubmed-meshheading:18050385-Pain Measurement,
pubmed-meshheading:18050385-Patient Satisfaction,
pubmed-meshheading:18050385-Quality of Life,
pubmed-meshheading:18050385-Severity of Illness Index,
pubmed-meshheading:18050385-Treatment Outcome
|
|
pubmed:year |
2008
|
|
pubmed:articleTitle |
Improved health-related quality of life for patients with active rheumatoid arthritis receiving rituximab: Results of the Dose-Ranging Assessment: International Clinical Evaluation of Rituximab in Rheumatoid Arthritis (DANCER) Trial.
|
|
pubmed:affiliation |
Seattle Rheumatology Associates, Seattle, WA 98104, USA. pmease@nwlink.com
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Research Support, Non-U.S. Gov't,
Multicenter Study
|
